Introduction
The clinical studies of Beatson reporting responses to oophorectomy in women with advanced breast cancer (Beatson 1896) provided the first experimental evidence that an ovarian factor was critical for continued tumour growth in a proportion of breast cancers. It took another 58 years for this factor to be identified as oestrogen (Pearson et al. 1954 ). Subsequent research employing experimental models of carcinogen-induced mammary carcinoma revealed that oestrogen was essential for both the initiation and progression of breast cancer (Henderson et al. 1988) . Studies with human breast cancer cell lines xenografted to athymic nude mice have demonstrated an absolute requirement for oestrogen in tumour formation and growth (Soule & McGrath 1980) . Such observations provided the rationale for the introduction of antioestrogen therapy, the current treatment of choice for hormone-responsive breast cancer (Jordan & Murphy 1991 (Sutherland etal. 1983a ). Using breast cancer cells synchronized at the Gi/S boundary or at G2/M to test the effect of oestrogen added at different stages of the cell cycle, Leung & Potter (1987) concluded that the sensitive cells were in early Gj phase, immediately following mitosis. These data supported observations that both non¬ steroidal (Sutherland etal. 1983b ) and steroidal antioestrogens (Wakeling etal. 1991 , Watts etal. 1995 (Taylor etal. 1983 ). Together these data are compatible with a model whereby oestrogens and antioestrogens, through their interactions with the ER, control the rate of transcription of genes that regulate key control points in Gt progression.
Candidate genes that might fulfil this role include 'immediate early' and 'delayed early' genes with established roles in signal transduction and cell cycle control. Of particular interest are the proto-oncogene c-myc, genes encoding components of the AP-1 tran¬ scription complex, c-fos and c-jun, and the more recently described cyclin/cyclin-dependent kinase (CDK) complexes involved in G[ progression. This report focuses on the latter pathway.
Progress through Gj phase requires inactivation of the pRB protein, the product of the retinoblastoma susceptibility gene RB-1, by phosphorylation and the consequent release of a number of pRB-bound mol¬ ecules including the E2F family of transcription factors. These factors then activate transcription of genes whose products are required for S phase progression (Riley etal. 1994 , Weinberg 1995 (Morgan 1994 , Sherr & Roberts 1995 (Matsushime etal. 1991) , consistent with the notion that these cyclins act as mitogenic sensors linking extracellular signals with cell cycle progression (Sherr 1993 ). An essential role for cyclin Dl in mammary gland devel¬ opment is demonstrated by the absence of lobuloalveolar structures in transgenic mice with disruption of the cyclin DI gene (Fanti etal. 1995 , Sicinski et al. 1995 . There is also accumulating evidence that D-type cyclins play a role in mediating the effects of growth factors and steroid hormones on breast cancer cell cycle progression by binding and activating Cdk4 (Musgrove etal. 1993 , 1996a , Sweeney etal. 1996 . The abundance of cyclin Dl increases following growth factor and progestin stimulation of breast cancer cell proliferation (Musgrove etal. 1993) and declines rapidly following exposure to growth-inhibitory antioestrogens (Musgrove etal. 1993 , Watts etal. 1995 . Similarly cyclin E expres¬ sion also increases following growth factor stimulation of breast cancer cells ), but at times later than for cyclin Dl and compatible with its established role in the control of the Gj to S phase transition. Finally, ectopie expres¬ sion of cyclin Dl in T-47D breast cancer cells is sufficient for Cdk4 and Cdk2 activation, pRB phos¬ phorylation and GpS phase progression (Musgrove etal. 1996¿> (GST- pRB773"923 substrate) was elevated 4.6-fold at 3 h after oestradiol treatment (Fig. 3) , maximally elevated at 6 h (6.6-fold) and thereafter declined. The initial changes in Cdk4 activity were temporally similar to those in expression for cyclin DI protein Time (h) Figure 3 Oestrogen induction of cyclin D-and cyclin Eassociated kinase activity. Cells were treated as outlined in Fig. 1 (Musgrove etal. 1994 (Musgrove etal. 1994) , the phenotype of transgenic mice (Wang et al. 1994) and data from experimental models of mammary carcinogenesis (Said et al. 1996 (Fanti et al. 1993 , Seshadri etal. 1996 , Sweeney etal. 1996 (Mclntosh etal. 1995, Gillett etal. 1996, Michalides etal. 1996) allowing some tenta¬ tive conclusions to be drawn. A relationship between cyclin Dl overexpression and ER positivity was observed as predicted from the amplification data and studies on mRNA levels (Buckley etal. 1993 , Hui etal. 1996 . Two studies examined an associa¬ tion between cyclin Dl overexpression and patient survival; one found no prognostic significance in a series of 248 patients (Michalides et al. 1996) while the other found that cyclin Dl overexpression was associated with a survival benefit in a population of 406 patients with long-term follow-up (Gillett etal. . Although all samples expressed detectable levels of cyclin Dl mRNA, these levels were signif¬ icantly higher in the ER-positive group and ER positivity increased from 58% in the lowest quartile of cyclin Dl (Watts etal. 1995).
To test the latter possibility we constructed clonai T-47D and MCF-7 cell lines in which cyclin Dl could be expressed under the control of the metalinducible, metallothionein promoter. Cells were then growth arrested with antioestrogens and the effects of ectopie expression of cyclin Dl assessed. Following induction of cyclin Dl gene expression, first evident at 3 h, antioestrogen-arrested cells began to progress into S phase by 9 h (Fig. 7) . A greater than 3-fold increase in S phase was apparent at 15 h as a significant proportion of the arrested population progressed semi-synchronously through the cell cycle to reach mitosis at about 21 h (Fig. 7) . Treatment with increasing concentrations of zinc resulted in a concentration-dependent increase in cyclin Dl protein and S phase fraction as described previously (Musgrove etal. 1994 cyclin D1-3 cells (Musgrove etal. 1994 ) were growth arrested as described in Fig. 1 (Gillett etal. 1996) , Sweeney etal. 1996 and may confer resistance to some forms of endocrine treatment (Wilcken et (Foster & Wimalasena 1996 ) and cyclin DI (Musgrove etal. 19966) 
Conclusions
Recent data from this laboratory (Prall etal. 1997) (Fanti etal. 1995 , Sicinski etal. 1995 . (Buckley etal. 1993) (Wang etal. 1994 , Said etal. 1996 . However, considerably more evidence will be required before definitive conclusions can be drawn on this subject.
Further preliminary data relating cyclin Dl expression to phenotype and disease outcome in primary breast cancer confirm a relationship between cyclin Dl expression and ER positivity (Hui etal. 1996) Since the development of resistance to tamox¬ ifen is a major limiting factor in the effective management of hormone-responsive breast cancer (Katzenellenbogen 1991) (Musgrove etal. 1993 , Watts etal. 1995 , Altucci etal. 1996 , Foster & Wimalasena 1996 , Prall etal. 1997 
